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Emmanouil S. Brilakis, MD, PHD,y George D. Dangas, MD, PHDzSEE PAGE 2730P atients who undergo surgery after coronarystent implantation are at risk for perioperativestent thrombosis, a highly morbid compli-
cation that can be particularly challenging to treat
because the often necessary antithrombotic medica-
tions markedly increase the risk for bleeding at the
surgical site (1,2).
In a landmark study of >40,000 patients, Hawn
et al. (3) previously identiﬁed 3 major factors associ-
ated with perioperative major adverse cardiac events
when noncardiac surgery is performed within 2 years
of stenting: 1) nonelective surgical admission; 2) his-
tory of myocardial infarction in the 6 months pre-
ceding surgery; and 3) revised Cardiac Risk Index
higher than 2. Timing of surgery after stenting ranked
ﬁfth in explanatory importance, and the risk was
similar regardless of stent type—drug-eluting (DES) or
bare-metal stent. The obvious clinical dilemma is the
selective interruption of the dual antiplatelet therapy
in a way that surgery would have acceptable bleeding
risk while minimizing the risk for stent thrombosis.
In this issue of the Journal, Holcomb et al. (4)
provide additional, novel information on the incre-
mental risk of noncardiac surgery on myocardial
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Sanoﬁ.surgery. After matching 20,590 surgical to 41,180
nonsurgical stent patients, the incremental risk for
adverse cardiac events with noncardiac surgery,
adjusted for surgical characteristics, was 2.8% during
the ﬁrst 6 weeks, 2.0% between 6 weeks and 6
months, and 0.9% after 6 months to 24 months,
driven by differences in myocardial infarction and
death. There are important “take-home” messages
from this study, in more than one aspect of this
complex clinical problem.First, it conﬁrms that the ﬁrst 6-weeks post-coro-
nary stenting is the highest risk period for periop-
erative complications, as suggested by a prior study
(5). Approximately 1 in 10 patients undergoing sur-
gery within 6 weeks from stenting had a major
adverse cardiac event, and the major adverse cardiac
event was related to stenting in 1 of 36 patients (4).
Therefore, stenting should be avoided if at all
possible in patients known to require noncardiac
surgery within 6 weeks. Medical therapy would be the
best option, with deferral of stenting until after
noncardiac surgery. If revascularization is absolutely
necessary (e.g., in patients with acute coronary syn-
dromes and unstable symptoms or left main disease)
for extensive multivessel disease, then coronary ar-
tery bypass graft surgery would be preferred, if
technically and clinically feasible/appropriate (2). If
percutaneous coronary intervention is performed, an
attempt to achieve a good result with balloon angio-
plasty alone might be preferable, as the risk for peri-
operative complications appears to be low after 2
weeks (6). If noncardiac surgery is performed early
after stenting, consideration should be given to
perioperative continuation of oral antiplatelet ther-
apy (3) (at least aspirin if P2Y12 inhibitor discontinu-
ation is mandated), or pre-operative “bridging” with a
glycoprotein IIb/IIIa inhibitor (7,8), although there
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2741are limited data to support either approach. In a
recent report from a large international registry, a
physician-driven, careful risk stratiﬁcation and se-
lective interruption of dual antiplatelet therapy were
found to be more frequent than expected and safer
than anticipated (9).
Second, it demonstrates that the risk for major
adverse cardiac events remains elevated between 6
weeks and 6months from stenting (1 in 20 patients had
a major adverse cardiac event, which was related to
stenting in 1 of 50 patients), and plateaus thereafter.
The 2014 American College of Cardiology/American
Heart Association perioperative management guide-
lines recommend delaying surgery for at least 12
months after DES implantation (Class I recommenda-
tion), yet suggest that 6 months may be enough “if the
risk of further delay is greater than the expected risks
of ischemia and stent thrombosis” (Class IIb recom-
mendation) (10). This study by Holcomb et al. (4),
which supports the latter recommendation, is in line
with another study showing that a shorter duration of
dual antiplatelet therapy after stenting may provide
similar (or better) outcomes compared with a longer
duration (11). A similar plateau of clinical events in
relation to antiplatelet therapy interruption also was
reported beyond 6 months (12).
Third, after 6 months the incremental risk stabi-
lized at approximately 1%, but continued out to at
least 24 months, and perhaps longer (13). This is in
agreement with a systematic review in which the
risk of perioperative stent thrombosis was 0.86%
when surgery was performed after 12 months from
stenting (5). It may, therefore, be best to perform
noncardiac surgery in patients with coronary stents
(regardless of when the stents were implanted)
at centers with coronary intervention capability,
to allow for prompt treatment if perioperative
myocardial infarction and stent thrombosis occur
(2). Fully bioabsorbable stents are currently available
for clinical use outside the United States and may
ultimately obviate the risk of very late stent
thrombosis, but this has not yet been suggested in
any clinical research study and the early risk of
major adverse cardiac events remains. In the in-
terim, we should pay close attention to the technicalaspects of coronary stent implantation, as explained
subsequently.
Fourth, the risk for perioperative major adverse
cardiac events early after stenting was higher among
high-risk patients undergoing complex procedures
and signiﬁcantly decreased after 6 months. These
patients may be most likely to beneﬁt from delaying
any surgery until 6 months after implantation.
Fifth, perioperative major adverse cardiac events
occurred more frequently with bare-metal stents than
DES. Although this appears paradoxical, it is likely
related to patient selection, with sicker patients
receiving bare-metal stents. Conversely, bare-metal
stent implantation may not be the optimal solution
in patients requiring early surgery. Indeed, the cobalt
chromium everolimus-eluting stent has a lower
overall (not perioperative) risk for stent thrombosis
(14). Very late perioperative stent thrombosis can
still occur with second-generation DES (13), although
the risk may be lower with DES with biodegradable or
nonthrombogenic polymers.
Approximately 1 in 5 patients require noncardiac
surgery within 2 years post-stenting (15). Attention
to meticulous stent implantation technique with
the avoidance of edge dissection/trauma, under-
expansion, or malapposition; careful consideration
of all factors that may lead to unwanted disruption of
dual antiplatelet therapy; and utilization of stent
types that offer advantages with respect to stent
thrombosis are all necessary steps for clinical success.
Careful stratiﬁcation of patients on the basis of clin-
ical and angiographic risks (16) and the inclusion of all
medical and surgical colleagues in a careful assess-
ment of the timing of surgery, bleeding risks, and the
individualized modes of antiplatelet therapy inter-
ruption are also extremely important. The contribu-
tion by Holcomb et al. (4) further enhances our ability
to provide optimal management and optimal out-
comes to these challenging-to-treat patients.
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